Showing results (101-110 of 121) with videos related to

Sort By:
Pageof 13
Journal of Inherited Metabolic Disease|April 16, 2024
Mass cytometry reveals atypical immune profile notably impaired maturation of memory CD4 T with Gb3-related CD27 expression in CD4 T cells in Fabry diseaseWladimir Mauhin, Gaelle Dzangue-Tchoupou, Damien Amelin, et al.
Neurology|January 14, 2018
Necrosis in anti-SRP+ and anti-HMGCR+myopathies: Role of autoantibodies and complementYves Allenbach, Louiza Arouche-Delaperche, Corinna Preusse, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 20, 2025
Impactor relics of CI-like chondrites in Chang'e-6 lunar samplesJintuan Wang, Zhiming Chen, Zexian Cui, et al.
Plos One|May 23, 2020
Cornea verticillata and acroparesthesia efficiently discriminate clusters of severity in Fabry diseaseWladimir Mauhin, Olivier Benveniste, Damien Amelin, et al.
Brain : a Journal of Neurology|May 10, 2018
JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositisLeandro Ladislau, Xavier Suárez-Calvet, Ségolène Toquet, et al.
JCO Clinical Cancer Informatics|March 1, 2024
Prediction of Effectiveness and Toxicities of Immune Checkpoint Inhibitors Using Real-World Patient DataLevente Lippenszky, Kathleen F Mittendorf, Zoltán Kiss, et al.
Orphanet Journal of Rare Diseases|August 2, 2018
Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRYWladimir Mauhin, Olivier Lidove, Damien Amelin, et al.
Neurology and Therapy|August 26, 2023
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 StudyJason Aldred, Eric Freire-Alvarez, Alexander V Amelin, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|May 18, 2017
[Diagnosis and treatment of migraine: Recommendations of the Russian experts]V V Osipova, E G Filatova, A R Artemenko, et al.
The Lancet. Rheumatology|January 26, 2024
Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trialOlivier Benveniste, Jean-Yves Hogrel, Lisa Belin, et al.
Pageof 13